Midostaurin: a specific drug for the treatment of blood diseases, detailed explanation of efficacy and indications

Midostaurin is a multi-target oral tyrosine kinase inhibitor with the trade name Rydapt. It was developed by Novartis and approved by the US FDA in 2017. It is the first targeted drug to be officially used to treat acute myeloid leukemia (AML) carrying FLT3 mutations. Its advent marks the official entry of AML treatment into the medical era, and has also become one of the representative drugs that have revolutionized treatment strategies in the field of hematological tumors in recent years. In addition to AML, midostaurin is also approved for the treatment of advanced systemic mastocytosis (SM), showing broad and stable efficacy in a variety of hematological diseases.

In the field of AML, about 30% of new AML patients have FLT3 mutations, mainly including FLT3-ITD (internal tandem duplication mutations) and FLT3-TKD (tyrosine kinase domain mutations). These mutations keep the FLT3 receptor active, thereby promoting abnormal proliferation of leukemia cells, inhibiting apoptosis, and leading to a higher risk of relapse and poorer overall survival. Midostaurin, as a multi-target tyrosine kinase inhibitor, can effectively inhibit the activity of FLT3 kinase, thereby blocking tumor signaling pathways and inhibiting the growth of leukemia cells. Unlike other more "narrow-spectrum" FLT3 inhibitors (such as giritinib), midostaurin can also act on other kinases, such as KIT, PDGFR, VEGFR, etc., theoretically giving it stronger anti-tumor ability.

The main indication of midostaurin is for newly treated patients with FLT3 mutation-positive acute myeloid leukemia (AML). It is not used as a single drug, but in combination with standard chemotherapy regimens, that is, it is administered in combination with cytarabine (Ara-C) and daunorubicin to form a "7+3" induction regimen, and it continues to be used in combination with chemotherapy during the consolidation treatment phase. The basis of this program comes from a pivotal phase III clinical trial, the RATIFY study, which enrolled 717 patients with FLT3-mutated AML aged 18 to 59 years old. The results showed that midostaurin combined with standard chemotherapy can significantly extend overall survival and significantly improve the five-year survival rate. This data makes midostaurin the first FLT3-targeted drug proven to prolong survival in first-line treatment, and is strongly recommended by NCCN and ELN guidelines as a standard treatment option for patients with previously untreated FLT3-mutated AML.

ExceptIn addition to AML, midostaurin is also used to treat a rare but very poor prognosis blood disease - systemic mastocytosis (SM). Such diseases include subtypes such as aggressive SM (ASM), SM-AHN with associated hematological neoplasms, and mast cell leukemia (MCL). The vast majority of patients have the KIT D816V mutation, which causes abnormal proliferation of mast cells and releases large amounts of histamine and other mediators, causing multi-system damage. Midostaurin can effectively reduce the number of mast cells, relieve symptoms and prolong progression-free survival by inhibiting the activity of KIT mutant protein. Clinical studies have shown that about 60% of SM patients have obtained clinical benefits after using midostaurin, including reduction in organ size, relief of symptoms, and improvement in quality of life.

Common side effects of midostaurin include nausea, vomiting, loss of appetite, fatigue, rash, nose bleeding, etc., which are generally mild to moderate. A few patients may experience QT interval prolongation or pulmonary toxicity. Therefore, regular electrocardiogram and pulmonary function monitoring are required during treatment. Unlike some late-line targeted drugs, midostaurin puts more emphasis on the synergistic effect with standard chemotherapy, which also means that its use places more emphasis on treatment timing, program design and individualized patient assessment.

Reference materials:https://medlineplus.gov/druginfo/meds/a617033.html